Date: 04/11/2023

Mutational Spectrum of the ABCA12 Gene and Genotype-Phenotype Correlation in a Cohort of 64 Patients with Autosomal Recessive Congenital Ichthyosis

Abstract

Autosomal recessive congenital ichthyosis (ARCI) is a non-syndromic congenital disorder of cornification characterized by abnormal scaling of the skin. The three major phenotypes are lamellar ichthyosis, congenital ichthyosiform erythroderma, and harlequin ichthyosis. ARCI is caused by biallelic mutations in ABCA12, ALOX12B, ALOXE3, CERS3, CYP4F22, NIPAL4, PNPLA1, SDR9C7, SULT2B1, and TGM1. The most severe form of ARCI, harlequin ichthyosis, is caused by mutations in ABCA12. Mutations in this gene can also lead to congenital ichthyosiform erythroderma or lamellar ichthyosis. We present a large cohort of 64 patients affected with ARCI carrying biallelic mutations in ABCA12. Our study comprises 34 novel mutations in ABCA12, expanding the mutational spectrum of ABCA12-associated ARCI up to 217 mutations. Within these we found the possible mutational hotspots c.4541G>A, p.(Arg1514His) and c.4139A>G, p.(Asn1380Ser). A correlation of the phenotype with the effect of the genetic mutation on protein function is demonstrated. Loss-of-function mutations on both alleles generally result in harlequin ichthyosis, whereas biallelic missense mutations mainly lead to CIE or LI.

Keywords: ABCA12, ARCI, harlequin ichthyosis, lamellar ichthyosis, congenital ichthyosiform erythroderm

1. Introduction

Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of disorders of cornification characterized by abnormal skin scaling over the whole body. ARCI belongs to the non-syndromic types of ichthyoses. Three major clinical phenotypes have been described for ARCI: lamellar ichthyosis (LI), congenital ichthyosiform erythroderma (CIE), and harlequin ichthyosis (HI). LI is characterized by large and dark scales without erythroderma, whereas CIE shows fine white scales with erythroderma. Collodion membrane at birth can be found in both LI and CIE. HI is the most severe form of ARCI. Affected newborns were mainly born preterm and classically show large, thick, plate-like scales covering the body with deep erythematous fissures, accompanied by characteristic facial features such as ectropium, eclabium, flattened ears, and nasal hypoplasia. Limbs with flexion contractures and hypoplastic digits often occur. HI is associated with increased perinatal mortality due to feeding problems, respiratory distress, increased water loss, electrolyte imbalances, impaired thermal regulation, and bacterial infections [1]. Intensive neonatal care can improve the survival of affected newborns. After infancy, patients show generalized red, scaly skin and often additional features such as alopecia and contractures of fingers. They are prone to hearing difficulties due to a blockade of the external auditory canal by skin residues. Different ophthalmologic problems are frequent. Some patients show developmental delay in different areas. Adults may develop inflammatory arthritis. Treatments for ARCI include emollients and other topical treatments as well as systemic agents such as retinoids, vitamin D and its analogs, anti-inflammatory drugs, enzyme replacement, and substitution therapies [2]. Erythema and disease severity highly correlate with IL-17 expression in ichthyosis. Therefore, IL-17/IL-23-targeting strategies can be another therapeutic option [3]. The IL-17A inhibitor secukinumab induced a significant reduction in erythema and scaliness and a resolution of ectropion in a patient with ABCA12-associated ARCI [4]. 3D models of ichthyotic skin equivalents provide new insights in dysregulated pathways as feasible therapeutic targets [5]. Gene therapy as a curative method is still at an early stage of development [6].

ARCI is caused by biallelic mutations in several genes: ABCA12, ALOX12B, ALOXE3, CERS3, CYP4F22, NIPAL4, PNPLA1, SDR9C7, SULT2B1, and TGM1. In patients with ARCI, mutations in TGM1 are found most frequently [7]. ABCA12 (ATP-binding cassette, subfamily A, member 12) was first described by Lefévre et al. [8] as a causative gene for LI. Later, pathogenic variants in ABCA12 were described to be causative for HI [9,10,11]. Mutations in ABCA12 can lead to HI, CIE, or LI depending on the type of the mutation. The main cause for HI are truncating mutations in ABCA12 (ichthyosis, congenital, autosomal recessive 4B (harlequin), and MIM #242500), whereas missense mutations in ABCA12 usually lead to milder phenotypes such as CIE or LI (ichthyosis, congenital, autosomal recessive 4A, and MIM #601277) [8,12]. The ABCA12 protein comprises 2595 amino acids and includes two transmembrane domains, each consisting of six hydrophobic membrane-spanning helices, and two ATP-binding cassettes, including highly conserved motifs (Walker A, Walker B, and active transport signature) [10]. Like many other genes implicated in ARCI, ABCA12 is a part of the ceramide pathway in the epidermis. Ceramides are important as free lipids in the extracellular space and for building the cornified lipid envelope (CLE). The CLE is a monolayer of lipids, which are an interface between the hydrophilic corneocytes and the lipophilic extracellular lipids and are therefore important for the skin barrier [13]. The protein-bound ceramides are formed in a cascade of reactions from sphingoid bases and fatty acids. ARCI-related genes and other skin-affecting genes are involved in many intermediate steps of these reactions [14]. ABCA12 is a keratinocyte transmembrane lipid transporter protein involved in the transport of lipids in lamellar granules (LG) to the apical surface of granular layer keratinocytes [10]. In healthy skin, the LGs fuse with the cell membrane in the interface of stratum granulosum and stratum corneum and discharge the content into the intercellular lamellae thus constituting a water-permeability barrier [15]. Mutations in ABCA12 lead to abnormal LGs or to a reduced number of LGs and an impaired transport of these granules, which results in a strong reduction in lipids in the intercellular spaces of the stratum corneum and a defective lipid barrier [12,15]. LGs originate from the Golgi apparatus, especially the trans-Golgi. Examination of isolated LGs revealed that they predominantly contain phosphoglycerides, sphingomyelin, and glucosylceramides. Furthermore, the lamellar bodies also contain enzymes such as acid hydrolases, including glucocerebrosidase, sphingomyelinase, and phospholipase A, as well as proteases and antimicrobial peptides [16].

In this study, we present a large cohort of 64 patients affected with ARCI carrying 62 different mutations in ABCA12. To date, 183 variants have been described as pathogenic for ARCI (HGMD® Professional version 2022.4). Here, we add 34 novel mutations in ABCA12, which expand the mutational spectrum of ABCA12-associated ARCI. Furthermore, our large cohort allows new insights into genotype–phenotype correlations in ABCA12.

2. Methods

In 64 patients with ARCI, mutations in ABCA12 were detected using different sequencing methods including Sanger sequencing or next generation sequencing (NGS). Due to the large time span of 28 years over which the patients were diagnosed, different sequencing methods were used. We present the results of the mutational analysis for only one affected individual from each family. This study was conducted according to the principles of the Declaration of Helsinki.

In all patients, genomic DNA was isolated from peripheral blood lymphocytes. Subsequently, PCR amplification, Sanger sequencing, or NGS methods through targeted multi-gene panels were performed. Most of our patients were analyzed through the targeted multi-gene panels HaloPlex Custom Kit or SureSelect Custom Kit (Agilent Technologies, Inc., Santa Clara, CA, USA). In all patients of our cohort, all coding exons and flanking intronic sequences (+/−20 base pairs) of ABCA12 (transcript ENST00000272895.7, RefSeq NM_173076.2, protein accession number NP_775099.2, GRCh37.p13) were analyzed. The resulting data were analyzed using an in-house bioinformatics pipeline and the commercial software SeqNext (JSI medical systems)

Alignments were retrieved from Ensembl 109 [17] using Eutheria Gen Tree node. Analysis and visualization were performed with Jalview version 2.11.1.3-j1.8 (https://www.jalview.org/, accessed on December 2022) [18]. The Genome Aggregation Database version v2.1.1 [19] and the ClinVar version, 10 December 2022 [20], were used. The classification of the detected sequence variants is based on the ACMG standards and guidelines [21].

3. Results

Genetic analysis of patients with ichthyosis revealed 64 families with mutations in ABCA12 in our laboratories. All patients and their mutations are listed in Table 1. We found 34 novel mutations in ABCA12, which are shown in bold in Figure 1A and Table 1. The classification of the novel mutations is presented in the Supplementary Materials, Table S1. All novel mutations in our cohort are classified as likely pathogenic or as pathogenic based on the ACMG standards and guidelines [21]. Our study increases the total number of known ABCA12 mutations to 217 (HGMD® Professional 2022.4).

3.1. Spectrum of Mutations in ABCA12

In our cohort of 64 patients, 62 different mutations were found occurring in a homozygous or compound heterozygous state, 34 of which are novel mutations. Due to the very rare occurrence of the mutations in ABCA12, patients with homozygous mutations usually have a consanguineous background. A total of 22 mutations of our cohort (35.5%) were missense mutations, 17 mutations (27.5%) were small deletions or duplications predicted to lead to a frameshift and premature stop codon, 14 mutations (22.5%) were nonsense mutations with a stop at this amino acid position, and 9 mutations (14.5%) were splice site mutations with a predicted effect on the splicing process (Figure 1B). In summary, 35.5% were missense mutations affecting one amino acid, whereas 64.5% were mutations that are predicted to have a larger effect on the protein, suggesting a greater influence on the severity of the disease.

1A, all mutations detected in our cohort and their distribution across the ABCA12 protein are shown. A total of 29 of 62 mutations are located within important protein domains: the transmembrane domains 1 and 2 and the ATP-binding cassette 1 and 2. A total of 18 of the 22 missense mutations are located in one of these domains, with 14 of these occurring in the ATP-binding cassettes. This suggests that a pathogenic effect of a missense mutation on the protein function is particularly large when the missense mutation is located in a functionally important domain of the ABCA12 protein. In regions outside of these domains, only 4 missense mutations were found, along with 29 nonsense, truncating, or splice-site mutations.

The comparison with the literature showed similar results. We investigated previously published missense variants in ABCA12, which were classified as pathogenic for ARCI (data from HGMD^® Professional 2022.4). A total of 72 missense mutations have been communicated to date, including the novel missense mutations of our cohort. Although only about 35% of the amino acids in ABCA12 are located in the domains mentioned above, they contain 75% of all reported missense mutations (54 of 72).

3.2. Mutational Hotspots in ABCA12

To analyze possible mutational hotspots in ABCA12, we counted the number of alleles for each mutation in our cohort. Except for 2 mutations, the number alleles for each mutation ranged from 1 to 4. A total of 2 mutations occurred significantly more frequently: c.4541G>A, p.(Arg1514His) with 11 alleles and c.4139A>G, p.(Asn1380Ser) with 25 alleles. It must be noted that most of the patients carrying these mutations were of North African origin; therefore, a founder mutation cannot be excluded. However, the mutation c.4139A>G, p.(Asn1380Ser) was also found in patients from other origins (Table 1 and in previously published patient studies).

Furthermore, we analyzed all known amino acid changes at the positions 1514 and 1380. At position 1514, we also found the exchange from arginine to cystine in our cohort. In the literature, exchanges from arginine at position 1514 to leucine and glutamine have also been described as pathogenic. At amino acid position 1380, no additional amino acid changes have been described. All these facts are strong indications for hotspot positions in ABCA12.

3.3. Genotype–Phenotype Correlation

To examine the genotype–phenotype correlation, we analyzed the kind of mutation and the phenotype of each patient of our cohort. Detailed clinical information about the phenotype was obtained in the majority of the patients (Table 1). The phenotypes of 49 patients of our cohort could be clearly assigned to HI, CIE, or LI (Figure 1C). A total of 21 patients presented as HI, 20 patients as CIE, and 8 patients as LI (Figure 1C). The subdivision into these three main phenotypes is not always clearly feasible, since the phenotypes are sometimes overlapping. A very severe ichthyosis congenita can show similarities to HI. Some patients show characteristics of both CIE and LI. Furthermore, therapeutic treatment can alter the phenotype. This leads to the result that 15 patients of our cohort could not be classified according to the three main phenotypes. Nevertheless, clear genotype–phenotype correlations can be identified: about one third of the patients (21 of 64) in our cohort were born with HI, and most of them carry biallelic truncating mutations (Figure 1D). Some patients with HI carry one truncating mutation on one allele and a splice site or missense mutation on the other allele. In contrast, patients with CIE (20 of 64) and LI (8 of 64) did not carry truncating mutations on both alleles. Most of these patients carry missense mutations on both alleles or show the combination of a missense mutation and a truncating mutation. Taken together, a combination of a truncating mutation and a missense mutation can lead to all phenotypes, whereas two truncating mutations were only found in HI patients in our cohort. Missense mutations on both alleles mainly lead to CIE or LI. A selection of patients of our cohort with the phenotypes HI, CIE, and LI are shown in Fig.ure 2

(A–D) Harlequin ichthyosis in patient 36. (A) Generalized dry and red scaly skin on the back, (B) palmoplantar hyperkeratosis, (C) joint contractures at fingers and thickened fingernails, and (D) face with red, scaly skin, ectropion, and hypoplastic ears. (E) Harlequin ichthyosis in patient 26 at the day of birth. Large thick plates separated by deep cracks. Ectropion, eclabion, hypoplastic nose and ears. (F–H) Lamellar ichthyosis in patient 48. (F) Palmoplantar hyperkeratosis, (G) ichthyotic skin on the neck, and (H) skin with large dark scales and contractures of fingers. (I–L) Congenital ichthyosiform erythroderma in patient 26. (I) Thickened skin with white scales in a newborn, (J) erythroderma of the palms, (K) generalized erythroderma with fine white scales, and (L) palmoplantar hyperkeratosis.

4. Discussion

The mutational spectrum of ABCA12 mutations in our cohort comprises 22 missense mutations (35.5%) and 40 truncating or splice-site mutations (64.5%). The percentage of missense mutations in our cohort is higher than in the cohort of Akiyama et al. [12] who found 14 missense mutations (25%) from a total of 56 homozygous or compound heterozygous mutations.

A total of 18 of 22 missense mutations of our cohort were located in one of the 2 transmembrane domains or ATP-binding cassettes, reflecting the importance of these domains for the function of the ABCA12 protein. Combining our findings with the already published mutations in the literature, about 73% of the missense mutations were located in these domains. The ATP-binding cassettes seem to be particularly important, as most missense mutations were found here. Missense variants in these conserved regions of the ABCA12 gene limit the function of the protein and therefore lead to an ARCI phenotype. Our results support previous findings of the importance of these domains [8,12]. For classification of unknown variants, the localization inside or outside these domains should be considered, especially for missense variants. Contrarily, truncating mutations in our cohort are distributed over the entire gene. This type of mutation has a greater impact on the protein due to a truncated protein or nonsense-mediated delay and therefore results in a more severe phenotype.

In our cohort, 2 mutations occur significantly more frequently: c.4541G>A, p.(Arg1514His) in 11 alleles and c.4139A>G, p.(Asn1380Ser) in 25 alleles. In Lefévre et al. [8], the mutation p.(Asn1380Ser) was already detected in five of nine families of North African origin. Due to the Northern African origin of most of the patients carrying these mutations, a founder mutation can contribute to the higher frequency of these mutations in the cohort. However, the mutation p.(Asn1380Ser) was also found in our cohort in patients from other regions and ethnicities (Table 1). Furthermore, at amino acid position 1514, different amino acid exchanges occur. All these facts are an indication for possible hotspot positions in ABCA12.

Patients with HI and CIE in our cohort occur at a comparatively equivalent ratio of about one third each. LI occurs less frequently. In just under a quarter of the patients, classification as one of the main phenotypes was not possible. This can be explained by insufficient information about the phenotype or by overlapping phenotypes. Some patients show features of both CIE and LI. In severe cases, some patients cannot not be clearly assigned to HI, but they show a milder phenotype, also known as chrysalis babies [24].

Our results confirm previous findings that the complete loss of ABCA12 function due to truncating mutations on both alleles generally leads to a HI phenotype. The combination of two missense mutations can lead to all phenotypes but mainly result in CIE or LI. Three of our patients with LI carried one truncating mutation and one missense mutation. In previous publications, only missense mutations have been described in patients with LI [8,25]. Our results show that the combination of a truncating mutation and a missense mutation can also lead to an LI phenotype.

In molecular genetic diagnostics, analysis of the ABCA12 gene may reveal only one heterozygous mutation. In cases with a CIE or LI phenotype, it should be considered that these phenotypes also occur in other genes associated with ARCI. In some of these cases, the cause of the disease may be in another gene, and the patient may additionally carry a heterozygous mutation in ABCA12. Therefore, if a phenotype cannot be clearly assigned to one gene, all genes associated with that phenotype should be investigated. In contrast to LI and CIE, the HI phenotype is highly specific for ABCA12 mutations. If only one heterozygous mutation is detected, it is likely that the second mutation is present but not yet found. Larger deletions, regulatory mutations, deep intronic mutations, or complex rearrangements should be considered.

Our findings contribute to a better understanding of the pathogenesis of ABCA12 mutations, the importance of ABCA12 domains, mutational hotspot positions, and genotype–phenotype correlations. Especially, the knowledge of the expected phenotype can improve prenatal diagnosis as well as neonatal care. However, intrafamilial phenotypic variation cannot be excluded. Furthermore, in large genes such as ABCA12, many variants with unclear pathogenicity are identified by molecular genetic analyses. Variants already described in patients with ARCI aid in the classification of novel variants and in establishing a correct diagnosis. The expanding of the mutational spectrum of ABCA12 mutations in our study supports a precise molecular genetic diagnostics in ARCI. Proper genetic counseling and molecular genetic diagnostics are very important for the affected families to find a strategy for disease management. For pregnant carrier women who are at high risk of having a severely affected child, invasive procedures such as chorionic villus sampling and amniocentesis and subsequent molecular genetic diagnostics is a commonly chosen method. Prenatal testing in the first trimester using cell-free DNA (NIPT) is a non-invasive method which may also be performed more frequently in the future for monogenetic diseases. In highly consanguineous marriage populations, screening of pregnant women for autosomal recessive diseases, e.g., by NIPT, may represent a method for the early detection and prevention of recessive diseases among the population [26].To date, there is no cure for ARCI, but symptomatic treatment options are increasing. In future, gene therapy may become a promising cure for this genetic disorder.

Acknowledgments

The authors are grateful to the patients and their families for supporting this study. We would like to thank Tobias Muehlbacher for providing a patient picture. This study is part of the European Reference Network—ERN SKIN.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/genes14030717/s1, Table S1: classification of the novel mutations in ABCA12.

Funding Statement

This research received no external funding.

Author Contributions

Study design, conceptualization, coordination of the project and writing J.F.; writing and construction of tables and figures A.H.; contribution of photos from patients E.B., F.S., L.W.; molecular genetic analysis A.H., J.K., A.D.Z., S.A., contribution of patients for analysis E.B., V.O., K.S., K.K., B.B., I.T.-P., M.H.P., R.C.B., K.G., F.S., L.W., S.S., D.V.S., G.T., E.D., K.B. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

This study was approved with the IRB number EK-Freiburg 20-1185.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data is contained within the article or supplementary material.

Conflicts of Interest

The authors declare no conflict of interest.

Go to:

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Rajpopat S., Moss C., Mellerio J., Vahlquist A., Gånemo A., Hellstrom-Pigg M., Ilchyshyn A., Burrows N., Lestringant G., Taylor A., et al. Harlequin ichthyosis: A review of clinical and molecular findings in 45 cases. Arch. Dermatol. 2011;147:681–686. doi: 10.1001/archdermatol.2011.9. [PubMed] [CrossRef] [Google Scholar]

2. Vahlquist A., Fischer J., Törmä H. Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment. Am. J. Clin. Dermatol. 2018;19:51–66. doi: 10.1007/s40257-017-0313-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Paller A.S., Renert-Yuval Y., Suprun M., Esaki H., Oliva M., Huynh T.N., Ungar B., Norma Kunjravia N., Friedland R., Peng X., et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J. Allergy Clin. Immunol. 2017;139:152–165. doi: 10.1016/j.jaci.2016.07.019. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Albela H., Leong K.F. Secukinumab in the treatment of a child with congenital ichthyosiform erythroderma with ABCA12 mutation. Int. J. Dermatol. 2023;62:e27–e29. doi: 10.1111/ijd.16378. [PubMed] [CrossRef] [Google Scholar]

5. Enjalbert F., Dewan P., Caley M.P., Jones E.M., Morse M.A., Kelsell D.P., Enright A.J., O’Toole E.A. 3D model of harlequin ichthyosis reveals inflammatory therapeutic targets. J. Clin. Investig. 2020;130:4798–4810. doi: 10.1172/JCI132987. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Chulpanova D.S., Shaimardanova A.A., Ponomarev A.S., Elsheikh S., Rizvanov A.A., Solovyeva V.V. Current Strategies for the Gene Therapy of Autosomal Recessive Congenital Ichthyosis and Other Types of Inherited Ichthyosis. Int. J. Mol. Sci. 2022;23:2506. doi: 10.3390/ijms23052506. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Fischer J. Autosomal recessive congenital ichthyosis. J. Investig. Dermatol. 2009;129:1319–1321. doi: 10.1038/jid.2009.57. [PubMed] [CrossRef] [Google Scholar]

8. Lefévre C., Audebert S., Jobard F., Bouadjar B., Lakhdar H., Boughdene-Stambouli O., Blanchet-Bardon C., Heilig R., Foglio M., Weissenbach J., et al. Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum. Mol. Genet. 2003;12:2369–2378. doi: 10.1093/hmg/ddg235. [PubMed] [CrossRef] [Google Scholar]

9. Kelsell D.P., Norgett E.E., Unsworth H., The M.-T., Cullup T., Mein C.A., Dopping-Hepenstal P.J., Dale B.A., Tadini G., Fleckman P., et al. Mutations in ABCA12 Underlie the Severe Congenital Skin Disease Harlequin Ichthyosis. Am. J. Hum. Genet. 2005;76:794–803. doi: 10.1086/429844. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Akiyama M., Sugiyama-Nakagiri Y., Sakai K., McMillan J.R., Goto M., Arita K., Tsuji-Abe Y., Tabata N., Matsuoka K., Sasaki R., et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J. Clin. Investig. 2005;115:1777–1784. doi: 10.1172/JCI24834. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Thomas A.C., Cullup T., Norgett E.E., Hill T., Barton S., Dale B.A., Sprecher E., Sheridan E., Taylor A.E., Wilroy R.S., et al. ABCA12 is the Major Harlequin Ichthyosis Gene. J. Investig. Dermatol. 2006;126:2408–2413. doi: 10.1038/sj.jid.5700455. [PubMed] [CrossRef] [Google Scholar]

12. Akiyama M. ABCA12 mutations and autosomal recessive congenital ichthyosis: A review of genotype/phenotype correlations and of pathogenetic concepts. Hum. Mutat. 2010;31:1090–1096. doi: 10.1002/humu.21326. [PubMed] [CrossRef] [Google Scholar]

13. Boiten W., Helder R., van Smeden J., Bouwstra J. Selectivity in cornified envelop binding of ceramides in human skin and the role of LXR inactivation on ceramide binding. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2019;1864:1206–1213. doi: 10.1016/j.bbalip.2019.05.003. [PubMed] [CrossRef] [Google Scholar]

14. Gutiérrez-Cerrajero C., Sprecher E., Paller A.S., Akiyama M., Mazereeuw-Hautier J., Hernández-Martín A., González-Sarmiento R. Ichthyosis. Nat. Rev. Dis. Primers. 2023;9:2. doi: 10.1038/s41572-022-00412-3. [PubMed] [CrossRef] [Google Scholar]

15. Hovnanian A. Harlequin ichthyosis unmasked: A defect of lipid transport. J. Clin. Investig. 2005;115:1708–1710. doi: 10.1172/JCI25736. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Wertz P. Epidermal Lamellar Granules. Skin Pharmacol. Physiol. 2018;31:262–268. doi: 10.1159/000491757. [PubMed] [CrossRef] [Google Scholar]

17. Cunningham F., Allen J.E., Allen J., Alvarez-Jarreta J., Amode M.R., Armean I.M., Austine-Orimoloye O., Azov A.G., Barnes I., Bennett R., et al. Ensembl 2022. Nucleic Acids Res. 2022;50:D988–D995. doi: 10.1093/nar/gkab1049. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Waterhouse A.M., Procter J.B., Martin D.M.A., Clamp M., Barton G.J. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25:1189–1191. doi: 10.1093/bioinformatics/btp033. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alföldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P., et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–443. doi: 10.1038/s41586-020-2308-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Landrum M.J., Lee J.M., Benson M., Brown G.R., Chao C., Chitipiralla S., Gu B., Hart J., Hoffman D., Jang W., et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D1067. doi: 10.1093/nar/gkx1153. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405–424. doi: 10.1038/gim.2015.30. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Paysan-Lafosse T., Blum M., Chuguransky S., Grego T., Pinto B.L., Salazar G.A., Bileschi M.L., Bork P., Bridge A., Colwell L., et al. InterPro in 2022. Nucleic Acids Res. 2022;51:D418–D427. doi: 10.1093/nar/gkac993. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Letunic I., Khedkar S., Bork P. SMART: Recent updates, new developments and status in 2020. Nucleic Acids Res. 2021;49:D458–D460. doi: 10.1093/nar/gkaa937. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Ahmed H., O’Toole E.A. Recent advances in the genetics and management of harlequin ichthyosis. Pediatr. Dermatol. 2014;31:539–546. doi: 10.1111/pde.12383. [PubMed] [CrossRef] [Google Scholar]

25. Akiyama M. Pathomechanisms of harlequin ichthyosis and ABCA transporters in human disesases. Arch. Dermatol. 2006;142:914–918. doi: 10.1001/archderm.142.7.914. [PubMed] [CrossRef] [Google Scholar]

26. Alyafee Y., Al Tuwaijri A., Umair M., Alharbi M., Haddad S., Ballow M., Alayyar L., Alam Q., Althenayyan S., Al Ghilan N., et al. Non-invasive prenatal testing for autosomal recessive disorders: A new promising approach. Front. Genet. 2022;13:1047474. doi: 10.3389/fgene.2022.1047474. [PMC free article] [PubMed] [CrossRef] [Google Scholar]  

Similar articles

•           Genotype of autosomal recessive congenital ichthyosis from a tertiary care center in India.

Chiramel MJ, Mathew L, Athirayath R, Chapla A, Sathishkumar D, Mani T, Danda S, George R.Pediatr Dermatol. 2022 May;39(3):420-424. doi: 10.1111/pde.14944. Epub 2022 Apr 12.PMID: 35412663

•           Update on autosomal recessive congenital ichthyosis: mRNA analysis using hair samples is a powerful tool for genetic diagnosis.

Sugiura K, Akiyama M.J Dermatol Sci. 2015 Jul;79(1):4-9. doi: 10.1016/j.jdermsci.2015.04.009. Epub 2015 Apr 30.PMID: 25982146 Review.

•           Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis.

Simpson JK, Martinez-Queipo M, Onoufriadis A, Tso S, Glass E, Liu L, Higashino T, Scott W, Tierney C, Simpson MA, Desomchoke R, Youssefian L, SaeIdian AH, Vahidnezhad H, Bisquera A, Ravenscroft J, Moss C, O'Toole EA, Burrows N, Leech S, Jones EA, Lim D, Ilchyshyn A, Goldstraw N, Cork MJ, Darne S, Uitto J, Martinez AE, Mellerio JE, McGrath JA.Br J Dermatol. 2020 Mar;182(3):729-737. doi: 10.1111/bjd.18211. Epub 2019 Aug 26.PMID: 31168818

•           Autosomal Recessive Congenital Ichthyosis.

Richard G.2001 Jan 10 [updated 2017 May 18]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.PMID: 20301593 Free Books & Documents. Review.

•           Molecular epidemiology of non-syndromic autosomal recessive congenital ichthyosis in a Middle-Eastern population.

Mohamad J, Samuelov L, Malchin N, Rabinowitz T, Assaf S, Malki L, Malovitski K, Israeli S, Grafi-Cohen M, Bitterman-Deutsch O, Molho-Pessach V, Cohen-Barak E, Bach G, Garty BZ, Bergman R, Harel A, Nanda A, Lestringant GG, McGrath J, Shalev S, Shomron N, Mashiah J, Eskin-Schwartz M, Sprecher E, Sarig O.Exp Dermatol. 2021 Sep;30(9):1290-1297. doi: 10.1111/exd.14345. Epub 2021 Apr 15.PMID: 33786896

See all similar articles

References

1.        

1.         Rajpopat S., Moss C., Mellerio J., Vahlquist A., Gånemo A., Hellstrom-Pigg M., Ilchyshyn A., Burrows N., Lestringant G., Taylor A., et al. Harlequin ichthyosis: A review of clinical and molecular findings in 45 cases. Arch. Dermatol. 2011;147:681–686. doi: 10.1001/archdermatol.2011.9. - DOI - PubMed

2.        

1.         Vahlquist A., Fischer J., Törmä H. Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment. Am. J. Clin. Dermatol. 2018;19:51–66. doi: 10.1007/s40257-017-0313-x. - DOI - PMC - PubMed

3.        

1.         Paller A.S., Renert-Yuval Y., Suprun M., Esaki H., Oliva M., Huynh T.N., Ungar B., Norma Kunjravia N., Friedland R., Peng X., et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J. Allergy Clin. Immunol. 2017;139:152–165. doi: 10.1016/j.jaci.2016.07.019. - DOI - PMC - PubMed

4.        

1.         Albela H., Leong K.F. Secukinumab in the treatment of a child with congenital ichthyosiform erythroderma with ABCA12 mutation. Int. J. Dermatol. 2023;62:e27–e29. doi: 10.1111/ijd.16378. - DOI - PubMed

5.        

1.         Enjalbert F., Dewan P., Caley M.P., Jones E.M., Morse M.A., Kelsell D.P., Enright A.J., O’Toole E.A. 3D model of harlequin ichthyosis reveals inflammatory therapeutic targets. J. Clin. Investig. 2020;130:4798–4810. doi: 10.1172/JCI132987. - DOI - PMC - PubMed